With Dupixent driving growth, Sanofi touts 'vigorous defense' to extend US exclusivity

In its first quarter presentation, Sanofi highlighted that it has a “vigorous defense planned” to extend Dupixent’s exclusivity beyond March of 2031, when the U.S. patent protecting its compound expires. The blockbuster accounted for 40% of …